STOCK TITAN

Clene (CLNN) Financials

CLNN NASDAQ
FY2025 annual
Revenue $200K -41.5% YoY
Net Income -$26.2M n/m YoY
Free Cash Flow -$18.6M n/m YoY
Operating Cash Flow -$18.5M n/m YoY
Market Cap $50.7M as of Nov 20, 2026
Price / Sales 213x on $238K revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CLNN SEC filings page.

Clene Inc. (CLNN) reported $200K in revenue for fiscal year 2025, down 41.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CLNN FY2025

Clene remains development-stage: shrinking revenue sits beside continued R&D investment, persistent cash outflow, and liabilities exceeding assets.

In FY2025, revenue was $200K while R&D spending was $14.0M, so reported commercial activity remains too small to fund the development program. Operating cash flow was -$18.5M, closely tracking free cash flow of -$18.6M, indicating that operating losses—not heavy capital spending—drive nearly all cash use.

R&D fell from $20.1M in FY2024 to $14.0M in FY2025, yet the company still recorded a net loss of $26.2M; lower spending has not changed its development-stage economics. The combination of minimal revenue and continued research investment explains why accounting losses remain structurally large relative to sales.

Liabilities rose from 132.4% of assets in FY2024 to 197.0% in FY2025, reflecting an increasingly negative equity position rather than ordinary operating leverage. The current ratio fell to 0.8x, so current assets no longer matched current liabilities; the reported liquidity measure was 3.4 months of the latest annual outflow, underscoring reliance on financing alongside operations.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Clene Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-27.26

Clene Inc. scores -27.26, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $308.3M against total assets of $18.1M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak
1/9

Clene Inc. passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.

Earnings Quality No Cash Backing
N/A

Clene Inc. reported a net loss of $26.2M while operations used $18.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Clene Inc. reported an operating loss of $23.1M against $2.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$56K
YoY+273.3%
QoQ-37.8%
5Y CAGR-12.6%

Clene Inc. generated $56K in revenue in Q3 2026. This represents an increase of 273.3% from the same quarter a year earlier. Against the prior quarter it is down 37.8%.

EBITDA
-$6.0M
YoYn/m
QoQn/m
5Y CAGRn/m

Clene Inc.'s EBITDA was -$6.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
$3.9M
YoYn/m
QoQn/m
5Y CAGR-33.0%

Clene Inc. reported $3.9M in net income in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
$0.05

Clene Inc. earned $0.05 per diluted share (EPS) in Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$4.7M
YoYn/m

Clene Inc. recorded an outflow of $4.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

Cash & Debt
$9.9M
YoY+24.8%
QoQ+2.2%
5Y CAGR-30.4%

Clene Inc. held $9.9M in cash against $17.5M in long-term debt as of Q3 2026.

Shares Outstanding
14M
QoQ+12.1%
5Y CAGR+35.9%

Clene Inc. had 14M shares outstanding in Q3 2026. Against the prior quarter it is up 12.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
71.4%
YoY-28.6pp
QoQ+11.4pp

Clene Inc.'s gross margin was 71.4% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 28.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 11.4 percentage points.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is above 100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$4.4M
YoY+26.6%
QoQ+28.1%
5Y CAGR-6.3%

Clene Inc. invested $4.4M in research and development in Q3 2026. This represents an increase of 26.6% from the same quarter a year earlier. Against the prior quarter it is up 28.1%.

Capital Expenditures
$51K
YoY+363.6%

Clene Inc. invested $51K in capex in Q3 2026, funding long-term assets and infrastructure. This represents an increase of 363.6% from the same quarter a year earlier.

Share Buybacks

Not reported for Q3 2026.

CLNN Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLNN quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$56K+273.3%$90K+233.3%$15K-81.5%$77K-15.4%$15K-82.8%$27K-70.3%$81K+11.0%$91K-46.5%
Cost of Revenue$16Kn/m$36Kn/m$0-100.0%$23K+27.8%$0-100.0%$0-100.0%$20K+25.0%$18K-52.6%
Gross Profit$40K+166.7%$54K+100.0%$15K-75.4%$54K-26.0%$15K-78.3%$27K-63.0%$61K+7.0%$73K-44.7%
R&D Expenses$4.4M+26.6%$3.5M-1.2%$329K-77.8%$5.5M-1.2%$3.5M-21.4%$3.5M-15.3%$1.5M-74.8%$5.6M-16.6%
SG&A Expenses$1.9M-9.8%$1.9M-18.8%$1.7M-34.2%$2.0M-35.3%$2.1M-37.0%$2.4M-28.3%$2.7M-22.3%$3.2M-6.8%
Operating Income-$6.3Mn/m-$5.3Mn/m-$2.1Mn/m-$7.5Mn/m-$5.6Mn/m-$5.9Mn/m-$4.1Mn/m-$8.7Mn/m
EBITDA-$6.0Mn/m-$5.0Mn/m-$1.7Mn/m-$7.1Mn/m-$5.3Mn/m-$5.5Mn/m-$3.7Mn/m-$8.2Mn/m
Interest Expense$665K+2.5%$695K+2.4%$791K+30.1%$746K+44.6%$649K-36.5%$679K-47.0%$608K-51.1%$516K-57.0%
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Net Income$3.9Mn/m-$13.4Mn/m-$8.1Mn/m-$9.2Mn/m-$8.8Mn/m-$7.4Mn/m-$751Kn/m-$13.5Mn/m
EPS (Basic)$0.30-$1.08n/m-$0.69n/m-$0.88n/m-$0.85n/m-$0.78n/m-$0.09n/m-$1.67n/m
EPS (Diluted)$0.05N/AN/AN/A-$0.85N/AN/AN/A
Diluted Shares (Avg)15MN/AN/AN/A10MN/AN/AN/A

CLNN Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLNN quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$22.2M-0.7%$23.0M+4.1%$21.7M-14.4%$18.1M-33.7%$22.3M-29.3%$22.1M-45.1%$25.3M-43.8%$27.3M-47.8%
Current Assets$14.5M+14.4%$14.9M+24.4%$13.0M-11.2%$9.0M-44.4%$12.7M-35.7%$12.0M-57.1%$14.7M-54.3%$16.2M-58.4%
Cash & Equivalents$9.9M+24.8%$9.7M+32.8%$5.9M-39.6%$5.2M-57.3%$7.9M-45.9%$7.3M-66.4%$9.8M-54.8%$12.2M-57.8%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%$0-100.0%
Inventory$41K-32.8%$37K-53.2%$54K+42.1%$37K-45.6%$61K-52.3%$79K+113.5%$38K+2.7%$68K+83.8%
Accounts Receivable$43Kn/m$43Kn/mN/A$0-100.0%$0n/m$0n/m$0-100.0%$64K-55.2%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$37.0M+6.6%$47.8M+55.9%$40.5M+33.6%$35.7M-1.3%$34.7M-2.9%$30.7M-24.9%$30.3M-25.8%$36.2M-7.1%
Current Liabilities$17.1M+106.0%$4.9M-35.9%$6.7M-37.5%$10.8M+4.7%$8.3M-65.1%$7.6M-73.0%$10.8M-58.9%$10.3M-59.4%
Non-Current Liabilities$19.9M-24.7%$43.0M+86.0%$33.7M+72.8%$24.9M-3.7%$26.4M+122.2%$23.1M+81.0%$19.5M+33.5%$25.9M+90.2%
Long-Term Debt$17.5M-2.0%$17.6M+6.9%$17.7M+6.4%$17.8M+64.4%$17.9M+971.6%$16.5M+843.4%$16.6M+813.9%$10.8M+105.7%
Total Equity-$14.8Mn/m-$24.8Mn/m-$18.8Mn/m-$17.6Mn/m-$12.4Mn/m-$8.6Mn/m-$5.0M-216.6%-$8.9M-166.1%
Retained Earnings-$325.9Mn/m-$329.8Mn/m-$316.4Mn/m-$308.3Mn/m-$299.1Mn/m-$290.3Mn/m-$282.9Mn/m-$282.1Mn/m

Not reported in any period shown, so not listed: Goodwill.

CLNN Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLNN quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$4.6Mn/m-$2.6Mn/m-$4.5Mn/m-$4.8Mn/m-$4.0Mn/m-$4.7Mn/m-$5.0Mn/m-$4.9Mn/m
Depreciation & Amortization$349K-4.4%$353K-3.6%$355K-12.1%$360K-13.7%$365K-12.7%$366K-15.3%$404K-9.6%$417K-12.6%
Stock-Based Compensation$1.1M-36.6%$1.0M-23.9%$1.3M-32.6%N/A$1.7M-22.2%$1.4M-29.9%$1.9M-3.3%N/A
Capital Expenditures$51K+363.6%N/AN/A$28K+2700.0%$11K+1000.0%$0-100.0%$0-100.0%$1K-97.7%
Free Cash Flow-$4.7Mn/mN/AN/A-$4.8Mn/m-$4.0Mn/m-$4.7Mn/m-$5.0Mn/m-$4.9Mn/m
Investing Cash Flow-$51Kn/m-$1Kn/m$0n/m-$28Kn/m-$11Kn/m$0-100.0%$0-100.0%-$2Kn/m
Financing Cash Flow$4.9M+4.8%$6.3M+196.7%$5.2M+95.8%$2.1M-18.1%$4.6Mn/m$2.1M+7517.9%$2.7Mn/m$2.5Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CLNN Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CLNN quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin71.4%-28.6pp60.0%-40.0pp100.0%+24.7pp70.1%-10.1pp100.0%+20.7pp100.0%+19.8pp75.3%-2.8pp80.2%+2.6pp
Operating Margin-11333.9%-5941.1%-13740.0%-9733.8%-37653.3%-21718.5%-5032.1%-9511.0%
Net Margin6991.1%-14915.6%-53940.0%-11981.8%-58513.3%-27477.8%-927.2%-14889.0%
Return on Assets17.7%+57.0pp-58.3%-24.7pp-37.4%-34.4pp-50.9%-1.3pp-39.3%-14.0pp-33.5%-16.7pp-3.0%+21.6pp-49.6%-30.1pp
Current Ratio0.85-0.7x3.07+1.5x1.94+0.6x0.83-0.7x1.53+0.7x1.58+0.6x1.36+0.1x1.570.0x
Asset Turnover0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x
FCF Margin-8335.7%N/AN/A-6268.8%-26686.7%-17570.4%-6186.4%-5347.3%

Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity, Liabilities-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$17.6M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Note: The current ratio is below 1.0 (0.83), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Clene Inc. CLNN FY2025 $200K -$26.2M N/A $50.7M —
Lifevantage Corporation LFVN FY2026 $182.6M $5.1M 2.8% $52.6M 47/100
FitLife Brands, Inc. FTLF FY2025 $81.5M $6.3M 7.8% $58.2M 62/100
Beyond Meat, Inc. BYND FY2025 $275.5M $219.0M 79.5% $71.3M 26/100
Niagen Bioscience, Inc. NAGE FY2025 $129.4M $17.4M 13.4% $145.7M 68/100
Nature's Sunshine Products Inc. NATR FY2025 $480.1M $19.5M 4.1% $176.4M 56/100

Frequently Asked Questions

Clene Inc. (CLNN) reported $200K in total revenue for fiscal year 2025. This represents a -41.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Clene Inc. (CLNN) revenue declined by 41.5% year-over-year, from $342K to $200K in fiscal year 2025.

No, Clene Inc. (CLNN) reported a net loss of $26.2M in fiscal year 2025.

Clene Inc. (CLNN) had EBITDA of -$21.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Clene Inc. (CLNN) had $5.2M in cash and equivalents against $17.8M in long-term debt.

Clene Inc. (CLNN) had a gross margin of 78.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Clene Inc. (CLNN) recorded an outflow of $18.6M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Clene Inc. (CLNN) recorded an outflow of $18.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Clene Inc. (CLNN) had $18.1M in total assets as of fiscal year 2025, including both current and long-term assets.

Clene Inc. (CLNN) invested $39K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Clene Inc. (CLNN) invested $14.0M in research and development during fiscal year 2025.

Clene Inc. (CLNN) had 12M shares outstanding as of fiscal year 2025.

Clene Inc. (CLNN) had a current ratio of 0.83 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Clene Inc. (CLNN) had a return on assets of -144.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Clene Inc. (CLNN) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $50.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Clene Inc. (CLNN) trades at 213x sales, its market capitalization divided by $238K revenue, trailing 12 months to September 30, 2026. The market capitalization is $50.7M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Clene Inc. (CLNN) held $5.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $18.5M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Clene Inc. (CLNN) has negative shareholder equity of -$17.6M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Clene Inc. (CLNN) has an Altman Z-Score of -27.26, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Clene Inc. (CLNN) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Clene Inc. (CLNN) reported a net loss of $26.2M while operations used $18.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Clene Inc. (CLNN) reported an operating loss of $23.1M against $2.7M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top